Project description:The advent of immune checkpoint inhibition (ICI) has revolutionized cancer treatment, yet response rates remain modest, and mechanisms of resistance are poorly understood. Recent studies highlight the role of sialic acid-containing glycans and their interaction with sialic acid-binding immunoglobulin-like lectin (Siglec) receptors in the tumor microenvironment, offering a promising avenue for cancer immunotherapy. Myeloid cells, particularly tumor-associated macrophages (TAMs), mediate sialic acid-mediated immune suppression via Siglec receptors. Different approaches, including antibodies, sialidases, and glycomimetics, can block the sialic acid-Siglec pathway, with promising results in preclinical models and ongoing clinical trials. However, achieving sufficiently high intratumoral sialidase levels without systemic toxicity remains a challenge.

2026-05-07 | GSE292054 | GEO

Inhaled nebulized glatiramer acetate against Gram-negative bacteria is not associated with adverse pulmonary reactions in healthy, young adult female pigs.

Project description: Not available

| S-EPMC6786617 | biostudies-literature

Qingkailing injection induces pseudo-allergic reactions via the MRGPRX2 pathway.

Project description: Not available

| S-EPMC11982860 | biostudies-literature

SLC10A4 regulates IgE-mediated mast cell degranulation in vitro and mast cell-mediated reactions in vivo.

Project description: Not available

| S-EPMC5430724 | biostudies-literature

Inflamed Ulcerative Colitis Regions Associated With MRGPRX2-Mediated Mast Cell Degranulation and Cell Activation Modules, Defining a New Therapeutic Target.

Project description: Not available